DeepMed Research

Innovent Biologics (Suzhou) Co., Ltd

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

IBI112 in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment

Phase 3

Active, not recruiting

Conditions: Psoriasis

Interventions: Drug: IBI112/placebo
Drug: IBI112

First Posted Date: 2023-09-22

Last Posted Date: 2024-08-02

Lead Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

Target Recruit Count: 550

Registration Number: NCT06049810

Locations: 🇨🇳
Shanghai Skin Disease Hospital, Shanghai, Shanghai, China

A Study of IBI129 in Subjects with Unresectable, Locally Advanced or Metastatic Solid Tumors

Phase 1

Recruiting

Conditions: Solid Tumor

Interventions: Drug: IBI129

First Posted Date: 2023-08-14

Last Posted Date: 2024-11-28

Lead Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

Target Recruit Count: 180

Registration Number: NCT05991349

Locations: 🇦🇺
Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia
🇦🇺
Wollongong Hospital, Wollongong, New South Wales, Australia
🇨🇳
Hubei Cancer Hospital, Wuhan, Hubei, China

and more 4 locations

A Study to Evaluate the Efficacy and Safety of IBI302 in Subjects with NAMD

Phase 3

Active, not recruiting

Conditions: Neovascular Age-related Macular Degeneration

Interventions: Drug: Aflibercept Ophthalmic
Biological: IBI302

First Posted Date: 2023-08-02

Last Posted Date: 2025-03-13

Lead Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

Target Recruit Count: 600

Registration Number: NCT05972473

Locations: 🇨🇳
Shanghai General Hospital, Shanghai, Shanghai, China

A Study of IBI112 in Chinese Patients With Psoriasis Who Were Previously Treated With Biologics

Phase 2

Completed

Conditions: Psoriasis

Interventions: Drug: regular treatment
Drug: Intensive treatment

First Posted Date: 2023-08-02

Last Posted Date: 2025-04-27

Lead Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

Target Recruit Count: 152

Registration Number: NCT05970978

Locations: 🇨🇳
Dermatology Hospital of Shandong First Medical University (Shandong Provincial Hospitial of Dermatology), Jinan, Shandong, China

Evaluation of IBI302 Injection in nAMD or DME

Phase 1

Suspended

Conditions: Neovascular Age-related Macular Degeneration
Diabetic Macular Edema

Interventions: Drug: Intravitreal injection of Aflibercept
Biological: Intravitreal injection of IBI302(dose 1)
Biological: Intravitreal injection of IBI302(dose 2)
Biological: Intravitreal injection of IBI302(dose 3)

First Posted Date: 2023-07-27

Last Posted Date: 2023-07-27

Lead Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

Target Recruit Count: 234

Registration Number: NCT05961007

Locations: 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China

A Clinical Study of IBI130 for Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors

Phase 1

Recruiting

Conditions: Solid Tumor

Interventions: Drug: IBI130

First Posted Date: 2023-06-28

Last Posted Date: 2023-11-29

Lead Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

Target Recruit Count: 182

Registration Number: NCT05923008

Locations: 🇦🇺
Sunshine Coast University, Birtinya, Queensland, Australia

A Clinical Trial Evaluating the Efficacy and Safety of IBI310 in Combination With Sintilimab, for Neoadjuvant Treatment of MSI-H/dMMR Resectable Colon Cancer

Phase 3

Recruiting

Conditions: MSI-H

Interventions: Drug: IBI310&Sintilimab
Drug: Sintilimab
Procedure: Radical surgery

First Posted Date: 2023-06-06

Last Posted Date: 2024-03-15

Lead Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

Target Recruit Count: 360

Registration Number: NCT05890742

Locations: 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

Parsaclisib in Patients With Relapsed or Refractory Follicular Lymphoma

Phase 1

Withdrawn

Conditions: Follicular Lymphoma

Interventions: Drug: rituximab
Drug: lenalidomide
Drug: parsaclisib

First Posted Date: 2023-05-19

Last Posted Date: 2023-10-17

Lead Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

Registration Number: NCT05867030

The Study of Tusamitamab Ravtansine (IBI126) Combined With Sintilimab and Tusamitamab Ravtansine (IBI126) Combined With Sintilimab Plus Platinum-based Chemotherapy and Pemetrexed in Subjects With CEACAM5 Positive Expression Advanced/Metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)

Phase 2

Terminated

Conditions: Non-squamous Non-small-cell Lung Cancer

Interventions: Drug: Tusamitamab ravtansine+Sintilimab
Drug: Tusamitamab ravtansine+Sintilimab+Carboplatin or Cisplatin+Pemetrexed
Drug: Sintilimab+Carboplatin or Cisplatin+Pemetrexed

First Posted Date: 2023-05-08

Last Posted Date: 2024-08-20

Lead Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

Target Recruit Count: 4

Registration Number: NCT05849246

Locations: 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

A Study to Evaluate the Drug-drug Interactions (DDIs) of IBI362 With Metformin, Warfarin, Atorvastatin, Digoxin in Overweight or Obese Subjects

Phase 1

Completed

Conditions: Overweight Subjects
Obese Subjects

Interventions: Drug: metformin
Drug: warfarin
Drug: digoxin
Drug: IBI362
Drug: atorvastatin

First Posted Date: 2023-04-18

Last Posted Date: 2023-11-14

Lead Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

Target Recruit Count: 48

Registration Number: NCT05815680

Locations: 🇨🇳
Aerospace Center Hospital, Beijing, Beijing, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy